Timothy A. Springer - Jan 17, 2024 Form 4 Insider Report for Cartesian Therapeutics, Inc. (RNAC)

Signature
/s/ Matthew Bartholomae, Attorney-in-Fact for Timothy A. Springer
Stock symbol
RNAC
Transactions as of
Jan 17, 2024
Transactions value $
$11,442
Form type
4
Date filed
3/28/2024, 05:11 PM
Previous filing
Jan 4, 2024
Next filing
Mar 18, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RNAC Common Stock Purchase $552 +800 +0.93% $0.69 87.2K Jan 17, 2024 By wife
transaction RNAC Common Stock Purchase $520 +800 +0.92% $0.65 88K Feb 6, 2024 By wife
transaction RNAC Common Stock Purchase $1.58K +2.4K +2.73% $0.66 90.4K Feb 7, 2024 By wife F1
transaction RNAC Common Stock Purchase $3.19K +4.8K +5.31% $0.66 95.2K Mar 8, 2024 By wife F2
transaction RNAC Common Stock Purchase $785 +1.2K +1.26% $0.65 96.4K Mar 11, 2024 By wife F3
transaction RNAC Common Stock Purchase $735 +1.2K +1.24% $0.61 97.6K Mar 12, 2024 By wife F4
transaction RNAC Common Stock Purchase $1.87K +3.2K +3.28% $0.58 101K Mar 13, 2024 By wife F5
transaction RNAC Common Stock Purchase $1.06K +2K +1.98% $0.53 103K Mar 14, 2024 By wife F6
transaction RNAC Common Stock Purchase $672 +1.2K +1.17% $0.56 104K Mar 15, 2024 By wife
transaction RNAC Common Stock Purchase $488 +800 +0.77% $0.61 105K Mar 18, 2024 By wife
holding RNAC Common Stock 7.47M Jan 17, 2024 Direct
holding RNAC Common Stock 33M Jan 17, 2024 See Footnote F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.65 to $0.67. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.65 to $0.68. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.65 to $0.66. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F4 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.61 to $0.62. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F5 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.58 to $0.59. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F6 The price reported is a weighted average price. The shares were purchased in multiple transactions at per share prices ranging from $0.52 to $0.54. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F7 Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any.